Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder

References

• KapurSAgidOMizrahiRLiMHow antipsychotics work-from receptors to realityNeuroRx200631102116490410
   PubMedGoogle Scholar
• MeltzerHYLiZKanedaYIchikawaJSerotonin receptors: their key role in drugs to treat schizophreniaProg Neuropsychopharmacol Biol Psychiatry20032771159117214642974
   PubMed Web of Science ®Google Scholar
• RowleyMBristowLJHutsonPHCurrent and novel approaches to the drug treatment of schizophreniaJ Med Chem200144447750111170639
   PubMed Web of Science ®Google Scholar
• KapurSZipurskyRJonesCRemingtonGHouleSRelationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophreniaAm J Psychiatry2000157451452010739409
   PubMed Web of Science ®Google Scholar
• GervinMBarnesTREAssessment of drug-related movement disorders in schizophreniaAdv Psychiatr Treat20006332341
   Google Scholar
• CavallaroRSmeraldiEAntipsychotic-induced tardive dyskinesia. Recognition, prevention and managementCNS Drugs199544278293
   Web of Science ®Google Scholar
• HaddadPMWieckAAntipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and managementDrugs200464202291231415456328
   PubMed Web of Science ®Google Scholar
• BouchardRHMeretteCPourcherELongitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study GroupJ Clin Psychopharmacol200020329530410831015
   PubMed Web of Science ®Google Scholar
• BeasleyCMJrTollefsonGTranPSatterleeWSangerTHamiltonSOlanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trialNeuropsychopharmacology19961421111238822534
   PubMed Web of Science ®Google Scholar
• MarderSRMeibachRCRisperidone in the treatment of schizophreniaAm J Psychiatry199415168258357514366
   PubMed Web of Science ®Google Scholar
• WeissEMBilderRMFleischhackerWWThe effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophreniaPsychopharmacology (Berl)20021621111712107611
   PubMed Web of Science ®Google Scholar
• BilderRMGoldmanRSVolavkaJNeurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorderAm J Psychiatry200215961018102812042192
   PubMed Web of Science ®Google Scholar
• LeuchtSPitschel-WalzGAbrahamDKisslingWEfficacy and extra-pyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trialsSchizophr Res199935151689988841
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical ExcellenceGuidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophreniaHealth Technology Appraisal No. 43;2002 URL http://www.nice.org.uk2002
   Google Scholar
• AshbyCRJrWangRYPharmacological actions of the atypical antipsychotic drug clozapine: a reviewSynapse199624434939410638826
   PubMed Web of Science ®Google Scholar
• MeltzerHYAlphsLGreenAIAltamuraACAnandRBertoldiAClozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)Arch Gen Psychiatry200360829112511175
   PubMed Web of Science ®Google Scholar
• KaneJHonigfeldGSingerJMeltzerHClozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazineArch Gen Psychiatry1988457897963046553
   PubMed Web of Science ®Google Scholar
• MeltzerHYBoboWVRoyAA randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophreniaJ Clin Psychiatry200869227428518232726
   PubMed Web of Science ®Google Scholar
• CaseyDEClozapine: neuroleptic-induced EPS and tardive dyskinesiaPsychopharmacology (Berl)198999SupplS47532682732
   PubMed Web of Science ®Google Scholar
• AtkinKKendallFGouldDFreemanHLiebermanJO’SullivanDNeutropenia and agranulocytosis in patients receiving clozapine in the UK and IrelandBr J Psychiatry19961694834888894200
   PubMed Web of Science ®Google Scholar
• MeltzerHYMatsubaraSLeeJCClassification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi valuesJ Pharmacol Exp Ther198925112382462571717
   PubMed Web of Science ®Google Scholar
• KapurSRemingtonGDopamineD(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficientBiol Psychiatry2001501187388311743942
   PubMed Web of Science ®Google Scholar
• WesterinkBHCan antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain?Eur J Pharmacol2002455111812433589
   PubMed Web of Science ®Google Scholar
• BaptistaTKinNMBeaulieuSde BaptistaEAObesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectivesPharmacopsychiatry200235620521912518268
   PubMed Web of Science ®Google Scholar
• MeltzerHYDavidsonMGlassmanAHViewegWVAssessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatmentJ Clin Psychiatry200263Suppl 9252912088173
   PubMed Web of Science ®Google Scholar
• LiebermanJADopamine partial agonists: a new class of antipsychoticCNS Drugs200418425126715015905
   PubMed Web of Science ®Google Scholar
• StahlSMDopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, “Goldilocks” actions at dopamine receptorsJ Clin Psychiatry2001621184184211775041
   PubMed Web of Science ®Google Scholar
• TohenMVietaECalabreseJEfficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression [published erratum: Arch Gen Psychiatry. 2004;61:176]Arch Gen Psychiatry200360111079108814609883
   PubMed Web of Science ®Google Scholar
• CalabreseJRKeckPEJrMacfaddenWA randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depressionAm J Psychiatry200516271351136015994719
   PubMed Web of Science ®Google Scholar
• JensenNHRodriguizRMCaronMGWetselWCRothmanRBRothBLN-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activityNeuropsychopharmacology200833102303231218059438
   PubMed Web of Science ®Google Scholar
• YathamLNGoldsteinJMVietaEAtypical antipsychotics in bipolar depression: potential mechanisms of actionJ Clin Psychiatry200566Suppl 5404816038601
   PubMed Web of Science ®Google Scholar
• CooksonJAtypical antipsychotics in bipolar disorder: the treatment of maniaAdv Psychiatr Treat2008145330338
   Google Scholar
• ShahidMWalkerGBZornSHWongEHAsenapine: a novel psychopharmacologic agent with a unique human receptor signatureJ Psychopharmacol2009231657318308814
   PubMed Web of Science ®Google Scholar
• MeltzerHYClinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophreniaPsychopharmacology (Berl)198999SupplS18272682729
   PubMed Web of Science ®Google Scholar
• MeltzerHYThe role of serotonin in antipsychotic drug actionNeuropsychopharmacology1999212 Suppl106S115S10432496
   PubMed Web of Science ®Google Scholar
• RothBLHanizavarehSMBlumAESerotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disordersPsychopharmacology (Berl)20041741172415205874
   PubMed Web of Science ®Google Scholar
• TaraziFIMoran-GatesTWongEHHenryBShahidMDifferential regional and dose-related effects of asenapine on dopamine receptor subtypesPsychopharmacology (Berl)2008198110311118297468
   PubMed Web of Science ®Google Scholar
• HuangMLiZDaiJShahidMWongEHMeltzerHYAsenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampusNeuropsychopharmacology200833122934294518418367
   PubMed Web of Science ®Google Scholar
• ReynoldsGPYaoZZhangXSunJZhangZPharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom responseEur Neuropsychopharmacol200515214315115695058
   PubMed Web of Science ®Google Scholar
• NealeACJenkinsHAmendDLesenMA 14 day dose escalation, double-blind, randomized, placebo-controlled study of SB518 in adult patients with schizophrenia [abstract]Neuropsychopharmacology200530Suppl 1S54
   Google Scholar
• HedlundPBSutcliffeJGFunctional, molecular and pharmacological advances in 5-HT7 receptor researchTrends Pharmacol Sci200425948148615559250
   PubMed Web of Science ®Google Scholar
• SvenssonTHAlpha-adrenoceptor modulation hypothesis of antipsychotic atypicalityProg Neuropsychopharmacol Biol Psychiatry20032771145115814642973
   PubMed Web of Science ®Google Scholar
• GhanbariRElMMShahidMBlierPElectrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brainEur Neuropsychopharmacol200919317718719116183
   PubMed Web of Science ®Google Scholar
• JoyceJNMillanMJDopamine D3 receptor antagonists as therapeutic agentsDrug Discov Today2005101391792515993811
   PubMed Web of Science ®Google Scholar
• MarstonHMYoungJWMartinFDAsenapine effects in animal models of psychosis and cognitive functionPsychopharmacology (Berl)2009
   Web of Science ®Google Scholar
• JentschJDShahidMWongERothRHAsenapine improves cognitive function in monkeys repeatedly exposed to the psychotomimetic drug phencyclidineSchizophr Res20068185
   Web of Science ®Google Scholar
• TaraziFIChoiYKGardnerMWongEHHenryBShahidMAsenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brainSynapse200963541342019177511
   PubMed Web of Science ®Google Scholar
• JohnsonDEYamazakiHWardKMInhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat isletsDiabetes20055451552155815855345
   PubMed Web of Science ®Google Scholar
• FranbergOWikerCMarcusMMAsenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophreniaPsychopharmacology (Berl)2008196341742917940749
   PubMed Web of Science ®Google Scholar
• PeetersPde GreefRHulskotteEAsenapine: an overview of phase I pharmacokinetic studies2009Paris, FrancePoster presented at 9th World Congress of Biological Psychiatry28 June–2 July 2009
   Google Scholar
• PotkinSGCohenMPanagidesJEfficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trialJ Clin Psychiatry200768101492150017960962
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar
• GuyWGuyWThe Clinical Global Impressions ScaleECDEU Assessment Manual for Psychopharmacology Rev EdRockville, MDNational Institute of Mental Health1976157169
   Google Scholar
• ChouinardGJonesBRemingtonGA Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patientsJ Clin Psychopharmacol199313125407683702
   PubMed Web of Science ®Google Scholar
• EmsleyRDoelderPDSchoemakerJNaberDLong-term safety of asenapine in patients with schizophreniaSchizophr Res200898Suppl 148
   Google Scholar
• PreskornSChapelSPanagidesJEffect of asenapine versus quetiapine and placebo on QTc interval in patients with schizophreniaEur Neuropsychopharmacol200717Suppl 4S453
   Web of Science ®Google Scholar
• FlemingKPotkinSGBinnemanBKellerDAlphsLPanagidesJEffects of asenapine on cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trialEur Neuropsychopharmacol200717Suppl 4S466
   Web of Science ®Google Scholar
• McIntyreRHirschfeldRAlphsLCohenMMacekTPanagidesJRandomized and placebo-controlled studies of asenapine in the treatment of acute mania in bipolar I disorderSchizophr Res200898Suppl 156
   Google Scholar
• YoungRCBiggsJTZieglerVEMeyerDAA rating scale for mania: reliability, validity and sensitivityBr J Psychiatry1978133429435728692
   PubMed Web of Science ®Google Scholar
• McIntyreRAlphsLCohenMKellerDSMacekTPanagidesJLong-term double-blind extention studies of asenapine vs. olanzapine in patients with bipolar maniaSchizophr Res200898Suppl 148
   Google Scholar
• TaylorDPatonCKapurSThe Maudsley Prescribing Guidelines10th EdLondon, UKInforma Healthcare2009
   Google Scholar